Biologic drugs (mAbs and biosimilars)
Monoclonal antibodies and other biologics targeting specific immune or growth pathways. Used in rheumatology, dermatology, gastroenterology, oncology, ophthalmology, and beyond. Specialty-tier with frequent prior-auth + step-therapy requirements.
What this class is
Biologics are large-molecule drugs derived from living systems — monoclonal antibodies, fusion proteins, cytokines, and other complex proteins. Major classes include TNF-α inhibitors (adalimumab, etanercept, infliximab), IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (guselkumab, risankizumab), IL-6 inhibitors (tocilizumab), CD20-directed (rituximab), CTLA-4 inhibitors, PD-1/PD-L1 checkpoint inhibitors, IgE-directed (omalizumab), and many more. Biosimilars are FDA-approved highly-similar versions of reference biologics.
Representative drugs
- Adalimumab (Humira) and biosimilars
- Etanercept (Enbrel)
- Infliximab (Remicade) and biosimilars
- Ustekinumab (Stelara)
- Secukinumab (Cosentyx)
- Dupilumab (Dupixent)
- Rituximab (Rituxan) and biosimilars
- Pembrolizumab (Keytruda)
Common denial patterns
- Step therapy requiring biosimilar first (newer Humira biosimilars)
- Step therapy across class (try MTX or oral DMARDs first)
- Prior auth missing specific lab values (e.g., disease activity scores)
- Site-of-care restrictions (must be home infusion, not hospital)
- Plan exclusion for cosmetic indications (e.g., dermatology)
Clinical guidelines that win appeals
- ACR Guidelines for RA Treatment — biologic recommendations
- AAD Psoriasis Treatment Guidelines
- AGA IBD Guidelines
- NCCN compendium for oncology biologics
Frequently asked questions
What is biologic drugs (mabs and biosimilars)?
Biologics are large-molecule drugs derived from living systems — monoclonal antibodies, fusion proteins, cytokines, and other complex proteins. Major classes include TNF-α inhibitors (adalimumab, etanercept, infliximab), IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (guselkumab, risankizumab), IL-6 inhibitors (tocilizumab), CD20-directed (rituximab), CTLA-4 inhibitors, PD-1/PD-L1 checkpoint inhibitors, IgE-directed (omalizumab), and many more. Biosimilars are FDA-approved highly-similar versions of reference biologics.
What are the common denial patterns?
Step therapy requiring biosimilar first (newer Humira biosimilars); Step therapy across class (try MTX or oral DMARDs first); Prior auth missing specific lab values (e.g., disease activity scores); Site-of-care restrictions (must be home infusion, not hospital); Plan exclusion for cosmetic indications (e.g., dermatology).
Which clinical guidelines support appeals?
ACR Guidelines for RA Treatment — biologic recommendations; AAD Psoriasis Treatment Guidelines; AGA IBD Guidelines; NCCN compendium for oncology biologics.
Related
- Specialty biologicsHumira, Enbrel, Stelara, Skyrizi, Cosentyx, Rinvoq, Dupixent
- Plaque psoriasis + psoriatic arthritisTNFi, IL-17, IL-23, IL-12/23, TYK2, JAK, PDE-4, topicals, phototherapy, biosimilars
- Inflammatory bowel disease (Crohn's + UC)TNFi, Stelara, Skyrizi, Tremfya, Entyvio, Rinvoq, Xeljanz, Zeposia, Velsipity, 5-ASA, TDM, surgery
- Lupus & rheumatologyBenlysta, Saphnelo, Lupkynis, hydroxychloroquine, MMF, rituximab, cyclophosphamide
- Antifibrotic agentsPirfenidone (Esbriet), nintedanib (Ofev) for idiopathic pulmonary fibrosis (IPF) and progressive pul
- BiosimilarsFDA-approved highly-similar versions of reference biologics. Plans frequently require biosimilar use
- Direct oral anticoagulants (DOACs)Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). Replaced warfar
- GLP-1 receptor agonistsSemaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Sax
Appeal a biologic drugs (mabs and biosimilars) denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com